An observational study in Coronary Artery Disease, Myocarditis and Infiltrative Cardiomyopathy, sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre · Observational
This study aims to identify and assess new CMR techniques that can improve current CMR protocols.
The aim of this study is to develop a comprehensive 10-minute protocol based on function and myocardial tissue characterization without the need for contrast injection, which can be standardized for 70% of cardiac patients.
To test this 10-minute CMR protocol for its ability to significantly improve diagnostic decision-making and to reduce cost.
To test its clinical feasibility, performance and cost-effectiveness in different populations including: Non-ischemic cardiomyopathies (-)OS-CMR and Ischemic Heart Disease and CAD (+)OS-CMR
4,857 studies on the registry are indexed under Coronary Artery Disease; 890 are open to participants now.
This study's planned enrollment of 2,130 is above the median of 320 across 1,687 observational studies indexed under Coronary Artery Disease.
Browse Coronary Artery Disease studies →McGill University Health Centre/Research Institute of the McGill University Health Centre is the lead sponsor of 421 studies on the registry; 105 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The study population will be composed of patients with suspected cardiovascular disease who are scheduled for a clinical CMR scan as part of a routine clinical work-up.
Patients will be stratified according to the clinical indication for CMR and their suspected or known clinical diagnosis.
Healthy Volunteers
Inclusion Criteria:
Exclusion Criteria:
Patients
Inclusion Criteria:
Exclusion Criteria:
Regular nicotine consumption during the last 6 months
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Age: \>18 y, No known current or pre-existing medical conditions that would affect the cardiovascular or respiratory system.
Age: \> 18y, Clinically indicated CMR exam
Primary diagnosis comparison between SMART CMR and standard CMR
(All patients) Agreement of the suggested primary diagnosis derived from SMART CMR, compared with the diagnosis established from standard CMR protocols, using the final clinical diagnosis as established by the treating physician, as a standard of truth. If the latter is not available, the conclusions based on the results of the standard CMR protocol will be used as the standard of truth.
Time frame: 2019-2025
Main finding comparison between SMART CMR and standard CMR in patients with suspected coronary artery disease
(Patients with suspected coronary artery disease:) Agreement of the main finding regarding the presence of a coronary territory at risk for inducible myocardial ischemia myocardial derived from OS-CMR, compared with standard first-pass perfusion CMR, using the coronary angiography report as a standard of truth. If the latter is not available, the conclusions based on the results of the standard CMR first pass perfusion scan will be used as the standard of truth.
Time frame: 2019-2025
SMART CMR scan completion percentage
Proportion of SMART CMR scans that could be completed according to the protocol
Time frame: 2019-2025
OS-CMR scan completion percentage
Proportion of OS-CMR scans that could be completed according to the protocol
Time frame: 2019-2025
Adverse event monitoring during SMART CMR sequences
Number and proportion of reported adverse events effects during SMART CMR
Time frame: 2019-2025
Adverse event monitoring during OS-CMR sequence
Number and proportion of reported adverse events during OS-CMR
Time frame: 2019-2025
SMART CMR sequence times vs standard protocol sequence times
Observed scan time for SMART CMR compared with the standard CMR protocol
Time frame: 2019-2025
OS-CMR sequence times vs standard protocol sequence times
Observed scan time for for OS-CMR during breathing maneuvers compared with the standard CMR first-pass perfusion protocol
Time frame: 2019-2025
Cost comparison of SMART CMR vs standard CMR protocol
Total estimated cost of SMART CMR compared with the standard CMR protocol
Time frame: 2019-2025
Cost comparison of OS-CMR vs standard CMR protocol
Total cost of OS-CMR with breathing maneuvers (based on scan time) vs the standard CMR first-pass perfusion protocol (calculated from the scan time plus any other material such as contrast agents or pharmacological vasodilators)
Time frame: 2019-2025
Septal myocardial T1 vs standard myocardial T1
Septal myocardial T1 as estimated from SMART CMR, compared with results from standard myocardial mapping
Time frame: 2019-2025
Septal myocardial T2 vs standard myocardial T2
Septal myocardial T2 as estimated from SMART CMR, compared with results from standard myocardial mapping
Time frame: 2019-2025
Quantitative parameter comparison between SMART CMR and CINE images
Quantitative parameters relevant to the diagnosis (see Appendix: CanSCMR Recommendations for reporting CMR) measured in SMART CMR images, compared with results from standard CMR cine images
Time frame: 2019-2025
Strain measurements vs standard cine image measurements
Longitudinal and circumferential strain measurements measured in SMART CMR images, compared with results from standard CMR cine images
Time frame: 2019-2025
SMART-CMR post-stenotic peak flow vs standard CMR flow images
Post-stenotic peak flow velocity in patients with suspected valvular disease measured in SMART CMR images, compared with results from standard CMR flow images
Time frame: 2019-2025
Intra- and inter-reader reproducibility
Correlation coefficients will be obtained to evaluate the intra- and inter-reader reproducibility of all quantitative markers.
Time frame: 2019-2025
Inter- and intra-scanner variability
Inter- and intra- scanner variability as assessed by ICC and kappa
Time frame: 2019-2025
Started Dec 2019 (actual). Primary completion is estimated for Dec 2026, 84 months after the start.
Of 634 non-industry observational studies under Coronary Artery Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 122. This study's planned 84 months is above that.
Counting every sponsor, half of 759 studies reached it within 40 months; a quarter within 21 and three quarters within 87.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 4, 2026: primary completion Nov 2024 → Dec 2026 and completion Jan 2025 → May 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
McGill University Health Centre/Research Institute of the McGill University Health Centre →